drugset / Trial / NCT02473887

Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting

NCT02473887

Phase 1 Completed 40 enrolled Hamad Medical Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to give children with gastroenteritis with persistent vomiting flavored intravenous ondansetron orally. The investigators test the palatability of the drug and check the serum level of ondansetron at 4 hours .

Timeline

Start
2014-09
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified Oral

Indications